Jemperli

Active Ingredient(s): Dostarlimab-gxly
FDA Approved: * April 22, 2021
Pharm Company: * GLAXOSMITHKLINE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Jemperli Overview

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as a medication for the treatment of endometrial cancer.[1][2][4][5] The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation.[1][2] Additional common side effects reported in the EU include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low lev...

Read more Jemperli Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dostarlimab

Recent Jemperli Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dostarlimab-gxly
  • Injection: 500mg/10ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Jemperli: (1 result)

Sorted by National Drug Code
  • 0173-0898 Jemperli 50 mg/ml Intravenous Injection by Glaxosmithkline LLC

Other drugs which contain Dostarlimab-gxly or a similar ingredient: (1 result)